Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Robert Marcus, Andrew Davies, Kiyoshi Ando, +15

New England Journal of Medicine

The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma

Jennifer L. Spratlin, Randeep Sangha, Darryl Glubrecht, +6

Clinical Cancer Research

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

Julie R. Brahmer, Jong-Seok Lee, Tudor–Eliade Ciuleanu, +21

Journal of Clinical Oncology

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles, +18

The Lancet Oncology

Lymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineImmunologyImmune Regulation +7

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, +36

Journal of Thoracic Oncology

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, +17

Journal of Clinical Oncology

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Martin Reck, Michael Schenker, Ki Hyeong Lee, +18

European Journal of Cancer

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada, +203

The Lancet Oncology

Lymphoid NeoplasiaEnd-of-induction Pet ResponseMedicinePrognostic ValueFollicular Lymphoma +5

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial

Peter Ellis, Frances A. Shepherd, Michael Millward, +20

The Lancet Oncology

Pretreated PatientsOncologyNcic Ctg Br.26Clinical TrialsImmune Checkpoint Inhibitor +7

A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors

Quincy S. Chu, Randeep Sangha, Jennifer L. Spratlin, +5

Investigational New Drugs

MedicineMetronomic TherapyAdvanced Solid TumorsCancer TreatmentOncology +4